Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: 20 December 2013 (Notification date: 23 December 2013).
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan.
- Price per ADS: $51.38.
- Individuals Involved: Dr. M. Slaoui (Director/PDMR) and Dr. K. Slaoui (Connected Person).
- ADS Quantity: Dr. M. Slaoui received 0 ADSs; Dr. K. Slaoui received 4 ADSs.